Literature DB >> 31161316

[Special treatment in rheumatology-cross-sectoral quality-oriented selective contracts].

E Edelmann1, F Schuch2, L Kalthoff3, S Zinke4.   

Abstract

In the last 4 years selective contracts according to §140a of the German Social Code Book V (SGB V) with three different health insurers were signed by the Professional Association of German Rheumatologists (BDRh) and from the beginning of the year 2018 by the management company of the association. The contracts were rolled out in five regions of Germany (Bavaria, Hesse, Mecklenburg-Western Pomerania, North Rhine and Saxony). Up to the end of 2018, 12,000 patients with chronic inflammatory rheumatic diseases were treated within the managed care of these contracts. The interface and the treatment pathways were initially consented with the associations of rheumatologists and general practitioners. The aim of the managed care was to provide the optimal quality in diagnostics and treatment and to improve management of rheumatic diseases. Quality indicators, such as treat-to-target principles, tight control, delegation to specially trained assistance personnel, patient education in rheumatoid arthritis (StruPi) and early arthritis consultation, are part of the managed care and are successfully promoted with incentive payments. Thus approximately 20% of the patients were enrolled for the first time in rheumatological care. The BDRh wants to promote the nationwide roll-out of this managed care in Germany with more participating health insurance funds.

Entities:  

Keywords:  Early outpatient consultation; Quality indicators; Rheumatological care; Specialist-oriented care; Treat to target

Mesh:

Year:  2019        PMID: 31161316     DOI: 10.1007/s00393-019-0630-y

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN: 0340-1855            Impact factor:   1.372


  2 in total

1.  [Treat to target: therapeutic aims/prognosis parameters].

Authors:  M Schneider; G-R Burmester
Journal:  Z Rheumatol       Date:  2019-06       Impact factor: 1.372

Review 2.  [Early recognition and screening consultation: a necessary way to improve early detection and treatment in rheumatology? : Overview of the early recognition and screening consultation models for rheumatic and musculoskeletal diseases in Germany].

Authors:  K Benesova; H-M Lorenz; V Lion; A Voigt; A Krause; O Sander; M Schneider; M Feuchtenberger; A Nigg; J Leipe; S Briem; E Tiessen; F Haas; M Rihl; D Meyer-Olson; X Baraliakos; J Braun; A Schwarting; M Dreher; T Witte; G Assmann; K Hoeper; R E Schmidt; P Bartz-Bazzanella; M Gaubitz; C Specker
Journal:  Z Rheumatol       Date:  2019-10       Impact factor: 1.372

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.